SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models
SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased
A small biotech company found their cancer drug works better alone and even better paired with another drug. When a company shows their medicine might fight cancer well, investors watch to see if those lab results lead to real patient wins.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.